Reduced cell-cell adhesion allows malignant epithelial cells to invade the basal membrane and penetrate the stroma. This implies the potential of the cells to escape from the @entity5 as well as spreading ability. Herein, we investigated the effects of @entity18789 (LA), a @entity1176 agonistic analogue, alone or in combination with @entity586 ( @entity587 ), on the expression of molecules involved in cell adhesion ( @entity5962 , @entity6076 , a-, b- and y-catenin) or in migration/invasion ( @entity1916 , CD44v6 and @entity5689 ) in @entity342 -sensitive (LNCaP) and -insensitive (PC-3) @entity263 (CaP) cells. We demonstrated by immunoblotting that, in LNCaP cells, molecules present in the adherens junctions ( @entity5962 , a-, b- and y-catenin) were expressed, while a-catenin was absent in PC-3 cells which expressed @entity6076 and @entity1916 . In LNCaP cells, no changes in @entity5962 levels were produced by 10(-9) M @entity587 while LA (10(-11) or 10(-6) M) up-regulated the protein level (up to 26-30% after 48 h). In the same cells, b- and y-catenin expression was enhanced either by @entity587 (24 and 20%, respectively) or LA (up to 18 and 40%, respectively), while a-catenin was not affected. Antagonistic effects were consistently observed between @entity587 and LA when the two hormones were jointly administered to the cells. Consistent results were obtained by immunocytochemistry. Co-immunoprecipitation analysis, used to verify the integrity of the LNCaP cell adhesion complex, demonstrated the association of @entity5962 with catenins. In PC-3 cells, adhesion molecule expression, analyzed by immunoblotting, was unaffected by LA, while a down-regulation of @entity1916 (up to 28%) was observed after 24 h of treatment but which did not hold up over time (48-144 h). Our findings demonstrate the efficacy of LA in upregulating @entity5962 , b- and y-catenin in LNCaP cells. This effect, that may be considered as another aspect of the direct antitumor activity of the @entity1176 analogue in hormone-dependent CaP cells, may contribute to maintenance/restoration of the normal tissue architecture counteracting the @entity5 cell spreading tendency.

@entity18789 affects adhesion molecule expression in human XXXX cells.

@entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity586 :: ('MESH:D013196', 'Chemical') :: ['dihydrotestosterone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor'] @entity5962 :: ('999', 'Gene') :: ['E-cadherin'] @entity5689 :: ('857', 'Gene') :: ['caveolin-1'] @entity18789 :: ('CHEBI:63597', 'Chemical') :: ['leuprorelin acetate'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH'] @entity1916 :: ('4233', 'Gene') :: ['c-met'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity587 :: ('CHEBI:16330', 'Chemical') :: ['DHT'] @entity6076 :: ('1000', 'Gene') :: ['N-cadherin']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
